AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (480)	8/18/1997 4:27:00 PM
From: David Bogdanoff	of 2173

IMO the stock is oversold at 8. Even if approved for only type 1 diabetes we would see good returns. I believe that better clinical studies will ultimately find appropriate subgroups and dosing patterns to result in substantial sales to type 2 diabetes patients also. Undoubtedly expectations got built into the price of the stock based on J&Js support and probably a naive belief that it would be a block-buster drug. It doesn't have to be a block-buster to be approved and profitable. Indeed, if it were a block-buster for a market the size of diabetes, it was underpriced at 16. The market seems to have trouble evaluating biotechs. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next